NEW YORK--(BUSINESS WIRE)--Glassbox (TASE: GLBX), the premier provider of AI-fueled customer intelligence solutions, today announced it has entered into a definitive agreement with Alicorn Venture ...
ALICORN Inc. announced today the addition of several new capabilities to its AI-powered healthcare platform, CareChat™, to support Direct Primary Care (DPC) Doctors. ALICORN launched the CareChat™ ...
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as AP2-associated protein kinase 1 (AAK1) inhibitors ...
Alicorn Pharmaceutical Co. Ltd. has divulged S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
With Alicorn’s support, we are ideally positioned to further accelerate our growth and continue leading innovation within the digital experience space.” Alicorn Venture Partners, a longstanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results